Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00640627 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

A Phase 4 study of Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 4
Development phase
380
Enrollment target
20
Study locations

NCT00640627 is a Phase 4 study of Osteoarthritis, Knee that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 380 participants, below the 576-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00640627, a Phase 4 study of Osteoarthritis, Knee, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 4
Development phase
380 participants
Enrollment target
20
Study locations

Study Summary

To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Conditions Studied

Osteoarthritis, Knee

Interventions

  • DRUG Placebo
  • DRUG Celecoxib

Study Locations (20)

Florida

  • Pfizer Investigational Site - DeLand
  • Pfizer Investigational Site - Naples
  • Pfizer Investigational Site - Pembroke Pines
  • Pfizer Investigational Site - St. Petersburg

California

  • Pfizer Investigational Site - Long Beach
  • Pfizer Investigational Site - Paramount
  • Pfizer Investigational Site - Tustin

Arizona

  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Tucson

Colorado

  • Pfizer Investigational Site - Colorado Springs
  • Pfizer Investigational Site - Wheat Ridge

Georgia

  • Pfizer Investigational Site - Woodstock

Kansas

  • Pfizer Investigational Site - Overland Park

Louisiana

  • Pfizer Investigational Site - New Orleans

Maryland

  • Pfizer Investigational Site - Baltimore

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2003-12
Est. Completion 2004-09
Phase Phase 4

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00640627

The ClinicalTrials.gov registry entry for NCT00640627 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 576-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (34% lower). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00640627 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00640627 about?

NCT00640627 is a clinical study titled "Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen". To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

What is the current status of trial NCT00640627?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 380 participants. The study started on 2003-12. Estimated completion is 2004-09.

What conditions does trial NCT00640627 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee.

What interventions are being tested in trial NCT00640627?

The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG).

Who is sponsoring clinical trial NCT00640627?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00640627 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoarthritis, Knee

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.